PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15292386-6	2004	RESULTS: Patients with HER-2/neu-positive tumors had a statistically significantly greater objective response rate than patients with HER-2/neu-negative tumors to treatment with ET (76% versus 50%, respectively; P =.005) but not to treatment with EC (46% versus 33%; P =.130).	ec	247-249	erb-b2 receptor tyrosine kinase 2	Homo sapiens	23-28	
15292386-6	2004	RESULTS: Patients with HER-2/neu-positive tumors had a statistically significantly greater objective response rate than patients with HER-2/neu-negative tumors to treatment with ET (76% versus 50%, respectively; P =.005) but not to treatment with EC (46% versus 33%; P =.130).	ec	247-249	erb-b2 receptor tyrosine kinase 2	Homo sapiens	29-32	
15218357-8	2004	With regard to progression-free survival, patients with elevated HER-2/neu ECD levels tended to benefit from ET (p = 0.0341), in patients with low levels no difference was observed between EC and ET.	ec	75-77	erb-b2 receptor tyrosine kinase 2	Homo sapiens	71-74